arrow
L

Li-Chuan Chan

university of texas system
H指数:30
被引数:7,836

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer

RNase1驱动的ALK激活是非小细胞肺癌中的致癌驱动因子和治疗靶点。

2025-04-180
OA
Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex
2022-10-1713
OAAI
ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer

ATR介导的CD47和PD-L1上调限制了结直肠癌放疗诱导的免疫启动和远位反应

2022-06-2480
OA
Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer
2022-04-0116
OA
Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation
2021-05-1320
OAAI
Targeting glycosylated PD-1 induces potent anti-tumor immunity
2020-08-151
PRE
Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity
2020-06-02115
OAAI
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer (vol 10, 5114, 2019)
2020-01-292
OAAI
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
2019-11-0875
OAAI
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
2019-07-15266
OA
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression
2019-06-03265
OAAI